Melanoma Treatment

Moderna’s Phase 3 Melanoma Win Reprices the Company

Late‑stage success for the personalized vaccine reduces clinical uncertainty for intismeran and has driven a sharp re‑rating of Moderna’s stock while key commercial questions remain.